We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pharmacielo Ltd | TSXV:PCLO | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -3.23% | 0.15 | 0.15 | 0.155 | 0.165 | 0.145 | 0.155 | 179,700 | 20:58:13 |
TORONTO and RIONEGRO, Colombia, April 9, 2019 /CNW/ - David Attard, Chief Executive Officer of PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the appointment of the Company's extended Medical and Scientific Advisory Board (MSAB).
"Global adoption of medical cannabis therapy is nearing a tipping point as acceptance by governments, healthcare practitioners and the public reaches a critical mass," said David Attard, Chief Executive Officer with PharmaCielo. "With the guidance of our new international Medical and Scientific Advisory Board, led by Dr. Delon Human, PharmaCielo is well positioned to become a global leader with medicinal cannabis offerings backed by enhanced medical and scientific research capabilities, advanced cultivation and extraction practices and the development of innovative products."
The mandate of the MSAB is to enhance PharmaCielo's research and product development plan, focused on the therapeutic properties of cannabinoid-based formulations. The MSAB will also provide guidance to PharmaCielo in safe and effective processes to use in the development of medicinal, consumer and pet health products – while adhering to stringent ethical research principles.
Dr. Delon Human, Global Head, Health and Innovation with PharmaCielo and Chair of the MSAB, noted, "The therapeutic potential of cannabinoids in helping to reduce human suffering and illness and to enhance well-being is enormous, and we have only scratched the surface of it. I believe that the members of PharmaCielo's MSAB have the unique opportunity to contribute to the development of the industry as a whole, by adhering to the same high standards of research and product identification used in related areas of medicinal research, as well as by focusing attention on the patient community."
The extended MSAB, consists of world-renowned experts from the medical, veterinarian, product R&D and academic fields, including:
About PharmaCielo
PharmaCielo Ltd. (TSXV:PCLO) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, "expects", "is expected", "intends", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be achieved. Forward-looking statements are based on assumptions, including with respect to PharmaCielo's planned products, and the ability to execute its business plan that management believes are reasonable in the circumstances, but the actual results, performance or achievements of PharmaCielo's business may be materially different from any future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including, but not limited to, the equity markets generally, risks associated with early stage companies, risks associated with the regulation of cannabis and cannabinoid derivatives, failure to obtain necessary TSXV approval, competition for PharmaCielo's planned products, risks associated with operating in Colombia, and currency exchange risk. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE PharmaCielo Ltd.
Copyright 2019 Canada NewsWire
1 Year Pharmacielo Chart |
1 Month Pharmacielo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions